Home › Trials › NCT06355050
Clinical trial Recruiting at 1 site Observational Ages 18 to 120 Men only

Adaptive ultra-short radiation therapy for early prostate cancer

Official title: Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer - Ultra-HART

Run by Jena University Hospital · NCT06355050 · Data updated 2026-11-12

This study tests how well ultra-hypofractionated adaptive radiation therapy works for men with early prostate cancer and how it affects their quality of life.

More Prostate Cancer trials

Quick facts

Study typeObservational
Ages18 Years to 120 Years
SexMen only
Enrollment150 (estimated)
SponsorJena University Hospital
Academic / other
Locations1 site (Jena)
StatusRecruiting
StartedApril 1, 2026
Main results expectedSeptember 30, 2027
Study endsSeptember 30, 2032
Registry record updatedJune 11, 2026
Trial IDNCT06355050 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients with early-stage prostate cancer, ECOG 0–1, not recently treated with androgen deprivation therapy, and without additional primary malignancies.

Probably not a fit

Patients with poor performance status, recent androgen deprivation therapy, or concurrent secondary cancers may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multi-center observational study conducted in Germany to see how tolerable ultrahypofractionated radiotherapy is for early prostate cancer when daily anatomy is corrected with an online-adaptive device. Patients complete digital QoL surveys over time, and toxicity and planning parameters are analyzed for correlations. The study compares QoL and toxicity outcomes with historical groups who received normofractionated or moderately hypofractionated RT. Lead site is Jena University Hospital, with collaboration from Stuttgart, Göttingen, and Aarau clinics. No intervention beyond standard-of-care radiotherapy is described in detail within the available information.

Why it matters

Potential benefit: If successful, the approach could improve quality of life and reduce treatment-related toxicity during prostate cancer radiotherapy.

How similar studies have gone: Prior studies using adaptive radiotherapy concepts have shown promise, but this specific ultra-hypofractionated, adaptive approach is being explored and may be comparatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* no androgen deprivation therapy within the last 2 months prior to RT
* good performance status (Eastern Cooperative Oncology Group, ECOG, 0/1)
* no secondary malignancy

Where it's running

  • Department of Radiotherapy and Radiation Oncology, Jena University Hospital
    Jena, Germany     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464Adaptive Radiotherapy 6Jena University Hospital 15
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.